{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Response that was confirmed on 2 consecutive evaluations during the first 4 months of treatment.\n\nComplete Response(CR): Disappearance of M-protein from serum and urine, normalization of Free Light Chain (FLC) ratio and \\<5% plasma cells in bone marrow.\n\nVery Good Partial Response(VGPR): \\>=90% reduction in serum M-component; Urine M-Component \\<100mg per 24hours.\n\nPartial Response(PR): \\>=50% reduction in serum M-component and/or Urine M-Component \\>=90% reduction or \\<200mg per 24hours; or \\>=50% decrease in difference between involved and uninvolved FLC levels.","groups":[{"description":"Anti-thymocyte Globulin (2.5 mg/Kg)and Melphalan (16 mg/m\\^2)","id":"OG000","title":"Anti-thymocyte Globulin/Melphalan"}],"paramType":"NUMBER","populationDescription":"One participant was evaluable for the primary endpoint.","reportingStatus":"POSTED","timeFrame":"4 months","title":"Hematological Response Rate Defined as the Number of Participants Who Achieve a Confirmed Response","type":"PRIMARY","unitOfMeasure":"participants"}